>> When does a phase III NSCLC trial start or is GENR waiting for a partner and/or buyout? <<
There probably won’t be a phase-3 trial in NSCLC unless the median survival of patients in the trial compares very favorably to historical results of stage-3b/4 patients who have received Paclitaxel+Carboplatin in the same setting.
If the Squalamine survival data are compelling, I would expect GENR to try to forge an out-licensing deal. I don’t think GENR wants to be in the oncology business.
Market Data 
Markets 
AI
